

# Er Blood Group Collection

## Number of antigens 3

High prevalence Er<sup>a</sup>, Er<sup>3</sup>  
 Low prevalence Er<sup>b</sup>

## Terminology

ISBT symbol (number) ER (208)  
 History Became a blood group collection in 1990.

## Phenotypes

Null Er(a–b–)

## Er<sup>a</sup> Antigen

### Terminology

ISBT symbol (number) ER1 (208001 or 208.1)  
 Obsolete names Rosebush; Ros; Min; Rod  
 History Reported in 1982; named after the first proband to make the antibody.

## Occurrence

Caucasians 1 in 100,000  
 With the exception of one Japanese woman (see below)  
 all Er(a–) probands have been of European ancestry

## Antithetical antigen

Er<sup>b</sup> (ER2)

## Expression

Cord RBCs Expressed  
 Altered RBCs from a Japanese woman and two of her  
 siblings reacted with three of eight anti-Er<sup>a</sup>

## Effect of enzymes and chemicals on Er<sup>a</sup> antigen on intact RBCs

Ficin/Papain	Resistant
Trypsin	Resistant
α-Chymotrypsin	Resistant
DTT 200 mM	Resistant
Acid	Sensitive

## *In vitro* characteristics of alloanti-Er<sup>a</sup>

Immunoglobulin class	IgG
Optimal technique	IAT

## Clinical significance of alloanti-Er<sup>a</sup>

Transfusion reaction	No to reduced RBC survival <sup>1</sup>
HDFN	Positive DAT but no clinical HDFN

## Comments

The mode of inheritance of Er<sup>a</sup> is unclear: one Er(a−) proband has two siblings, a mother, two aunts and an uncle, all of whom were Er(a−) suggesting the presence of a third allele.

The anti-Er<sup>a</sup> made by the Japanese proband gave slightly weakened reactions with trypsin-treated RBCs.

## Reference

- <sup>1</sup> Thompson, H.W., et al., 1985. Survival of Er(a+) red cells in a patient with allo-anti-Er<sup>a</sup>. Transfusion 25, 140–141.

## Er<sup>b</sup> Antigen

### Terminology

ISBT symbol (number)	ER2 (208002 or 208.2)
History	Reported in 1988, when the antibody was shown to recognize the antithetical low prevalence antigen to Er <sup>a</sup> .

### Occurrence

Most populations	<0.01%
------------------	--------

### Antithetical antigen

Er<sup>a</sup> (ER1)

Expression

Cord RBCs                      Expressed

Effect of enzymes and chemicals on Er<sup>b</sup> antigen on intact RBCs

Ficin/Papain	Resistant
Trypsin	Resistant
α-Chymotrypsin	Resistant
AET	Resistant

In vitro characteristics of alloanti-Er<sup>b</sup>

Immunoglobulin class	IgG
Optimal technique	IAT

Clinical significance of alloanti-Er<sup>b</sup>

Limited data because only two examples of anti-Er<sup>b</sup> have been reported.  
HDFN                      DAT+, but no clinical HDFN<sup>1</sup>

Reference

<sup>1</sup> Poole, J., et al., 2010. The second example of anti-Er<sup>b</sup> and its clinical significance in pregnancy [abstract]. Vox Sang 99 (Suppl. 1), 340.

Er3 Antigen

Terminology

ISBT symbol (number)	ER3 (208003 or 208.3)
History	An antibody made by a person with ER:–1,–2 RBCs with characteristics of antibodies in the ER collection was identified in 2000 and reported in detail in 2003 <sup>1</sup> . The antigen recognized by this antibody was named Er3 in 2004.

Occurrence

Most populations                      >99.9%

Expression

Cord RBCs                      Expressed

Effect of enzymes and chemicals on Er3 antigen on intact RBCs

Ficin/Papain	Presumed resistant
Trypsin	Presumed resistant
α-Chymotrypsin	Presumed resistant
DTT 200 mM	Presumed resistant
Acid	Sensitive

In vitro characteristics of alloanti-Er3

Immunoglobulin class	IgG
Optimal technique	IAT

Clinical significance of alloanti-Er3

Transfusion reaction	Mild in the only reported patient with anti-Er3
HDFN	No data because the only example of anti-Er3 was made by a male

Comments

Anti-Er3 reacted with RBCs from the only other Er(a–b–) person, whereas the antibody made by that person was compatible with RBCs from the maker of anti-Er3.

Reference

<sup>1</sup> Arriaga, F., et al., 2003. A new antigen of the Er collection. Vox Sang 84, 137–139.